| Field |
Value |
Language |
|
dc.contributor.author |
Sahu, P |
|
|
dc.contributor.author |
Donovan, C |
|
|
dc.contributor.author |
Paudel, KR |
|
|
dc.contributor.author |
Pickles, S |
|
|
dc.contributor.author |
Chimankar, V |
|
|
dc.contributor.author |
Kim, RY |
|
|
dc.contributor.author |
Horvart, JC |
|
|
dc.contributor.author |
Dua, K |
|
|
dc.contributor.author |
Ieni, A |
|
|
dc.contributor.author |
Nucera, F |
|
|
dc.contributor.author |
Bielefeldt-Ohmann, H |
|
|
dc.contributor.author |
Mazilli, S |
|
|
dc.contributor.author |
Caramori, G |
|
|
dc.contributor.author |
Lyons, JG |
|
|
dc.contributor.author |
Hansbro, PM |
|
|
dc.date.accessioned |
2023-09-27T05:33:29Z |
|
|
dc.date.available |
2023-09-27T05:33:29Z |
|
|
dc.identifier.citation |
Frontiers in Oncology, 13 |
|
|
dc.identifier.issn |
2234-943X |
|
|
dc.identifier.uri |
http://hdl.handle.net/10453/172332
|
|
|
dc.description.abstract |
<jats:p>Primary lung carcinoma or lung cancer (LC) is classified into small-cell or non-small-cell (NSCLC) lung carcinoma. Lung squamous cell carcinoma (LSCC) is the second most common subtype of NSCLC responsible for 30% of all LCs, and its survival remains low with only 24% of patients living for five years or longer post-diagnosis primarily due to the advanced stage of tumors at the time of diagnosis. The pathogenesis of LSCC is still poorly understood and has hampered the development of effective diagnostics and therapies. This review highlights the known risk factors, genetic and epigenetic alterations, miRNA biomarkers linked to the development and diagnosis of LSCC and the lack of therapeutic strategies to target specifically LSCC. We will also discuss existing animal models of LSCC including carcinogen induced, transgenic and xenograft mouse models, and their advantages and limitations along with the chemopreventive studies and molecular studies conducted using them. The importance of developing new and improved mouse models will also be discussed that will provide further insights into the initiation and progression of LSCC, and enable the identification of new biomarkers and therapeutic targets.</jats:p> |
|
|
dc.language |
en |
|
|
dc.publisher |
Frontiers Media SA |
|
|
dc.relation |
International Association for the Study of Lung Cancer Foundation |
|
|
dc.relation |
http://purl.org/au-research/grants/nhmrc/GNT1079187
|
|
|
dc.relation |
http://purl.org/au-research/grants/nhmrc/GNT1175134
|
|
|
dc.relation |
http://purl.org/au-research/grants/nhmrc/1138402
|
|
|
dc.relation |
http://purl.org/au-research/grants/nhmrc/1120152
|
|
|
dc.relation.ispartof |
Frontiers in Oncology |
|
|
dc.relation.isbasedon |
10.3389/fonc.2023.1260411 |
|
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
|
dc.rights |
This is an open-access article
distributed under the terms of the Creative
Commons Attribution License (CC BY). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms. |
|
|
dc.subject |
1112 Oncology and Carcinogenesis |
|
|
dc.subject.classification |
3202 Clinical sciences |
|
|
dc.subject.classification |
3211 Oncology and carcinogenesis |
|
|
dc.title |
Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions |
|
|
dc.type |
Journal Article |
|
|
utslib.citation.volume |
13 |
|
|
utslib.for |
1112 Oncology and Carcinogenesis |
|
|
pubs.organisational-group |
/University of Technology Sydney |
|
|
pubs.organisational-group |
/University of Technology Sydney/Strength - CFI - Centre for Inflammation |
|
|
utslib.copyright.status |
open_access |
* |
|
dc.date.updated |
2023-09-27T05:33:28Z |
|
|
pubs.publication-status |
Published online |
|
|
pubs.volume |
13 |
|
